Published in Biomark Med on February 01, 2010
Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol (2010) 1.59
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2013) 0.99
Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2014) 0.96
Update on Biomarkers for the Detection of Endometriosis. Biomed Res Int (2015) 0.90
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status. Alzheimers Dement (2013) 0.89
Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem (2016) 0.85
Plasma proteomics for the identification of Alzheimer disease. Alzheimer Dis Assoc Disord (2013) 0.85
Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement (2016) 0.84
Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease. Alzheimers Res Ther (2013) 0.84
Using biomarkers to improve detection of Alzheimer's disease. Neurodegener Dis Manag (2011) 0.84
Will posttranslational modifications of brain proteins provide novel serological markers for dementias? Int J Alzheimers Dis (2012) 0.81
Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimers Res Ther (2015) 0.81
Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Int J Mol Sci (2014) 0.80
Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation. J Transl Med (2012) 0.80
Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. Front Neurol (2015) 0.79
The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease. Front Neurol (2015) 0.79
Dietary methanol regulates human gene activity. PLoS One (2014) 0.78
Potential peripheral biomarkers for the diagnosis of Alzheimer's disease. Int J Alzheimers Dis (2011) 0.78
Blood metabolite markers of cognitive performance and brain function in aging. J Cereb Blood Flow Metab (2015) 0.78
Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. Neurodegener Dis Manag (2016) 0.77
Development of a standardized flow cytometric method to conduct longitudinal analyses of intracellular CD3ζ expression in patients with head and neck cancer. Oncol Lett (2016) 0.75
Exploring Biomarkers for Alzheimer's Disease. J Clin Diagn Res (2016) 0.75
Blood biomarkers for Alzheimer's disease. Genome Med (2014) 0.75
Biomarkers of Alzheimer's disease risk in peripheral tissues; focus on buccal cells. Curr Alzheimer Res (2014) 0.75
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
Detection of microRNA expression in human peripheral blood microvesicles. PLoS One (2008) 8.04
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A (2008) 5.24
Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol (2006) 4.77
Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol (1998) 4.48
Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics (2009) 4.27
Mining the plasma proteome for cancer biomarkers. Nature (2008) 4.10
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol (2004) 3.38
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A (2005) 2.75
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol (2000) 2.66
Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol (2006) 2.66
Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med (2009) 2.56
Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry (2008) 2.26
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr (2005) 2.16
Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials (2001) 2.06
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol (2003) 2.05
Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology (2007) 2.05
Proteome-based plasma biomarkers for Alzheimer's disease. Brain (2006) 1.98
The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis (2000) 1.94
Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.84
Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology (2007) 1.81
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology (2009) 1.70
MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders. Curr Genomics (2009) 1.60
Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol (2008) 1.59
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem (2005) 1.47
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol (2008) 1.46
Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett (2001) 1.44
MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio (2007) 1.43
Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke (2005) 1.42
Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis (2010) 1.41
Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging (2009) 1.40
Plasma homocysteine levels and risk of Alzheimer disease. Neurology (2004) 1.36
Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci U S A (2007) 1.35
Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology (2008) 1.32
Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS One (2008) 1.31
Mining biomarkers in human sera using proteomic tools. Proteomics (2004) 1.30
AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci (2009) 1.30
Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res (2006) 1.28
Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing (2003) 1.26
Oxysterols, cholesterol homeostasis, and Alzheimer disease. J Neurochem (2007) 1.26
Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev (2009) 1.25
Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci (2009) 1.24
Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2006) 1.23
Hyperhomocysteinemia and Alzheimer's disease: A systematic review. Arch Gerontol Geriatr (2008) 1.21
Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin Appl (2008) 1.20
In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med (2009) 1.20
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol (2008) 1.11
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging (2007) 1.10
The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett (2007) 1.09
Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement (2009) 1.09
Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci (1996) 1.08
Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun (2002) 1.08
Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement (2009) 1.08
Hydroxyoctadecadienoic acid and oxidatively modified peroxiredoxins in the blood of Alzheimer's disease patients and their potential as biomarkers. Neurobiol Aging (2007) 1.07
Affinity prefractionation for MS-based plasma proteomics. Proteomics (2009) 1.07
Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis (2000) 1.06
Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol (2008) 1.04
Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. Clin Chem Lab Med (2000) 1.04
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett (2005) 1.04
Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett (1998) 1.01
Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci Lett (2004) 1.00
Plasma/serum proteomics: pre-analytical issues. Expert Rev Proteomics (2007) 0.99
F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci (2007) 0.97
'How far' vs 'how fast' in Alzheimer's disease. The question revisited. Arch Neurol (1994) 0.96
Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis (2009) 0.94
Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study. Clin Chem (1998) 0.93
Is there a relationship between high C-reactive protein (CRP) levels and dementia? Arch Gerontol Geriatr (2009) 0.93
Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract (2007) 0.92
Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci Lett (1997) 0.92
Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. Expert Rev Proteomics (2007) 0.91
Plasma C-reactive protein is related to cognitive deterioration and dementia in patients with mild cognitive impairment. J Neurol Sci (2009) 0.88
The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers (2008) 0.87
Cross-linked fibrin degradation products (D-dimer), plasma cytokines, and cognitive decline in community-dwelling elderly persons. J Am Geriatr Soc (2003) 0.87
Multidimensional protein identification technology for clinical proteomic analysis. Clin Chem Lab Med (2009) 0.87
Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype. Neurobiol Aging (2009) 0.86
Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients. J Neurochem (2009) 0.86
Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.86
Identification of fast and slow decliners in Alzheimer disease: a different approach. Alzheimer Dis Assoc Disord (1995) 0.85
Plasma biomarkers of Alzheimer's disease. Curr Opin Psychiatry (2008) 0.85
Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study. Haemostasis (1999) 0.84
Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: relationship with dementia of Alzheimer's type. Int J Immunopathol Pharmacol (2005) 0.84
Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed Pharmacother (2007) 0.83
Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes. Schizophr Res (2008) 0.83
List of drugs in development for neurodegenerative diseases. Update June 2008. Neurodegener Dis (2008) 0.82
Plasma proteome analysis: 2D gels and chips. J Physiol Pharmacol (2006) 0.81
Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 0.81
Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia. Neurosci Lett (2007) 0.81
Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol Aging (2007) 0.81
Risk factors for dementia: data from the Conselice study of brain aging. Arch Gerontol Geriatr (2007) 0.80
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol (2012) 3.31
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry (2009) 3.15
Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr (2004) 2.54
The dementias. Lancet (2002) 2.42
A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet (2005) 2.04
Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A (2004) 1.95
Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci (2002) 1.83
Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet (2002) 1.77
Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol (2008) 1.74
DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet (2006) 1.73
Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis (2010) 1.73
The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet (2012) 1.71
SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet (2010) 1.58
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis (2007) 1.49
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage (2010) 1.44
The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry (2011) 1.35
Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage (2011) 1.34
Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology (2004) 1.32
Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage (2011) 1.30
Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis (2014) 1.29
Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun (2009) 1.28
MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci (2009) 1.28
Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing (2003) 1.26
Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol (2010) 1.26
Alpha-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. Neuromolecular Med (2004) 1.26
AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage (2011) 1.24
Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry (2010) 1.24
Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet (2010) 1.23
Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2005) 1.22
Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. Hum Mol Genet (2007) 1.16
Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc (2006) 1.15
Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study. J Alzheimers Dis (2010) 1.12
Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging (2013) 1.12
Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. Eur J Neurosci (2008) 1.12
Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis (2012) 1.11
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol (2008) 1.11
Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS One (2011) 1.10
Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groups--the AddNeuroMed study. Neurobiol Aging (2009) 1.09
Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study. Neurosci Lett (2004) 1.09
p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett (2007) 1.08
Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging (2010) 1.08
A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method. Neuroimage (2011) 1.06
Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One (2011) 1.06
The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05
A blood gene expression marker of early Alzheimer's disease. J Alzheimers Dis (2013) 1.05
Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Res (2013) 1.05
A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry (2008) 1.04
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett (2005) 1.04
Complement activation as a biomarker for Alzheimer's disease. Immunobiology (2011) 1.04
Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Hum Mol Genet (2007) 1.03
Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry (2012) 1.02
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet (2012) 1.02
The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology (2003) 1.01
Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease. J Alzheimers Dis (2013) 1.01
APOE ε2 allele is associated with larger regional cortical thicknesses and volumes. Dement Geriatr Cogn Disord (2010) 1.00
Education increases reserve against Alzheimer's disease--evidence from structural MRI analysis. Neuroradiology (2012) 0.99
Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis (2005) 0.99
Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis (2012) 0.99
Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One (2012) 0.98
Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease. J Alzheimers Dis (2011) 0.98
Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease. Ann Neurol (2006) 0.97
GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur J Neurosci (2006) 0.97
A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis (2009) 0.96
Diagnosing Alzheimer's disease--non-clinicians and computerised algorithms together are as accurate as the best clinical practice. Int J Geriatr Psychiatry (2007) 0.94
Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am J Med Genet B Neuropsychiatr Genet (2007) 0.93
Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis (2010) 0.92
Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. Am J Med Genet B Neuropsychiatr Genet (2005) 0.92
Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. Am J Med Genet B Neuropsychiatr Genet (2005) 0.92
Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging (2012) 0.92
OPCRIT+: an electronic system for psychiatric diagnosis and data collection in clinical and research settings. Br J Psychiatry (2011) 0.92
TAp73 isoforms antagonize Notch signalling in SH-SY5Y neuroblastomas and in primary neurones. J Neurochem (2006) 0.91
Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression. J Alzheimers Dis (2011) 0.91
No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2011) 0.91
PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS Lett (2006) 0.91
Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls. J Alzheimers Dis (2010) 0.91
Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease. Hum Genet (2003) 0.91
Genetic association of the APP binding protein 2 gene (APBB2) with late onset Alzheimer disease. Hum Mutat (2005) 0.90
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. J Clin Psychopharmacol (2009) 0.90
Positional pathway screen of wnt signaling genes in schizophrenia: association with DKK4. Biol Psychiatry (2007) 0.89
The NEO-FFI is a reliable measure of premorbid personality in patients with probable Alzheimer's disease. Int J Geriatr Psychiatry (2006) 0.89
Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging (2010) 0.88
Truncated apoE forms tangle-like structures in a neuronal cell line. Neuroreport (2002) 0.88
TAp73alpha induces tau phosphorylation in HEK293a cells via a transcription-dependent mechanism. Neurosci Lett (2006) 0.88
Plasma biomarkers for Alzheimer's disease: much needed but tough to find. Biomark Med (2012) 0.88
Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiol Aging (2012) 0.88
Nicastrin gene polymorphisms, cognitive ability level and cognitive ageing. Neurosci Lett (2005) 0.88
Wnt3a induces exosome secretion from primary cultured rat microglia. BMC Neurosci (2012) 0.87
Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiol Aging (2011) 0.87
Smell identification function as a severity and progression marker in Alzheimer's disease. Int Psychogeriatr (2013) 0.87